The Risk of Breakthrough Cardiac Events Associated With Psychiatric Medications in Patients With Diagnosed and Clinically Treated Long QT Syndrome
JACC: Clinical Electrophysiology · 2025-12 · 11 (12) · 2660-2669
DOI: 10.1016/j.jacep.2025.08.002 ↗Kurz gefasst
Fachartikel in der Zeitschrift JACC: Clinical Electrophysiology, 2025-12. Verfasst von Iuri Ferreira Felix und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/IuriFFelix. Hauptthemen laut MEDLINE: Long QT Syndrome, Psychotropic Drugs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Long QT syndrome (LQTS) is a potentially life-threatening genetic heart disease. Because many psychiatric medications have QT-prolonging potential, there is hesitation when prescribing them to LQTS patients with concomitant psychiatric disorders, which may lead to suboptimal mental health care. OBJECTIVES: This study sought to evaluate the incidence of breakthrough cardiac events (BCEs) in patients with diagnosed and clinically treated LQTS on QT-prolonging psychiatric medications. METHODS: Review of LQTS patients seen at the Mayo Clinic between January 2000 and December 2023 with a concomitant psychiatric diagnosis requiring medications with a QT-prolonging potential was performed. Follow-up time was defined as time from first evaluation in our clinic to the last communication for any LQTS-associated BCEs. RESULTS: Among 195 of 1,787 patients (11%) placed on psychiatric drugs (150 [76%] female, mean age at LQTS diagnosis 27 ± 18 years), the most common psychiatric disorders were depression (141 [71%]) and anxiety (120 [62%]). The most common prescribed medications were fluoxetine (53 [26%]), sertraline (27 [14%]) and escitalopram (22 [11%]). Before their first Mayo Clinic evaluation, 61 of 195 patients (31%) had at least 1 BCE. This occurred while on psychiatric medications for 7 patients (11%). Following their first Mayo Clinic evaluation, 14 of 195 patients (7%) had at least 1 BCE. This occurred while on psychiatric medications for 3 patients (21%). The 3 events happened in the setting of other known arrhythmia triggers including treatment noncompliance and electrolyte abnormalities. CONCLUSIONS: After correct diagnosis and treatment, LQTS patients with concomitant mental health issues may be safely and effectively treated with QT-prolonging psychiatric medications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: https://twitter.com/IuriFFelix.
- Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Molecular Pharmacology and Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota, USA; Medical Scientist Training Program, Mayo Clinic Alix Scho…
- Department of Cardiovascular Diseases, Division of Heart Rhythm Services, Windland Smith Rice Genetic Heart Rhythm Clinic, Mayo Clinic, Rochester, Minnesota, USA; Department of Molecular Pharmacology and Experimental Th…
Zitieren
APA
Ferreira Felix, I., Karlinski Vizentin, V., Neves, R., Bains, S., Bos, J. M., Giudicessi, J. R., & Ackerman, M. J. (2025). The Risk of Breakthrough Cardiac Events Associated With Psychiatric Medications in Patients With Diagnosed and Clinically Treated Long QT Syndrome. JACC: Clinical Electrophysiology, 11(12), 2660-2669. https://doi.org/10.1016/j.jacep.2025.08.002
Vancouver
Ferreira Felix I, Karlinski Vizentin V, Neves R, Bains S, Bos JM, Giudicessi JR, et al. The Risk of Breakthrough Cardiac Events Associated With Psychiatric Medications in Patients With Diagnosed and Clinically Treated Long QT Syndrome. JACC: Clinical Electrophysiology. 2025;11(12):2660-2669. doi:10.1016/j.jacep.2025.08.002
BibTeX
@article{FerreiraFelix2025,
author = {Ferreira Felix, Iuri and Karlinski Vizentin, Vanessa and Neves, Raquel and Bains, Sahej and Bos, J Martijn and Giudicessi, John R and Ackerman, Michael J},
title = {The Risk of Breakthrough Cardiac Events Associated With Psychiatric Medications in Patients With Diagnosed and Clinically Treated Long QT Syndrome},
journal = {JACC: Clinical Electrophysiology},
year = {2025},
volume = {11},
number = {12},
pages = {2660--2669},
doi = {10.1016/j.jacep.2025.08.002}
}
EUVIMED